Climb Bio, Inc. CLYM 深 滬
已收盤 02-06 16:00:00 美东时间
5.44
+0.790
+16.99%
華盛通- 最 高5.45
- 今 開4.72
- 成交量 89.37万股
- 最 低 4.698
- 昨 收 4.65
- 總市值 3.71亿
- 52周最高 5.60
- 市盈率 靜 --
- 換手率 1.31%
- 52周最低 1.05
- 委 比 -12.88%
- 總股本 6818.44万
- 歷史最高 29.69
- 量 比 2.02
- 振 幅 16.17%
- 歷史最低 1.05
- 每 手 1
- 風險率 1.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Climb Bio Announces First Patients Dosed In Budoprutug PrisMN Phase 2 Trial In pMN; Anticipates Data-Rich 2026, With Initial Readouts From All Ongoing Budoprutug And CLYM116 Studies
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory
01-08 20:13
Climb Bio Files Lawsuit Against Alumis And Acelyrin Seeking Declaratory Judgment Over Budoprutug Milestone Payment Dispute
On December 31, 2025, Climb Bio, Inc. (the "Company") filed a complaint (the "Complaint") in Delaware Superior Court against Alumis Inc. ("Alumis") and its wholly owned subsidiary, Acelyrin, Inc. ("Acelyrin"),
01-01 05:19
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $11
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $9 to $11.
2025-12-18 20:00
美股牛股 | B Riley金融大涨超53%，补交逾期第二季度报告，该季度实现扭亏为盈；Rezolve涨28%
B Riley金融大涨超53%，补交逾期第二季度报告，该季度实现扭亏为盈；Rezolve涨28%，预计年度经常性收入突破2亿美元，大幅超越此前目标>>
2025-12-17 18:50
美股牛股 | KYTX大涨超23%，Miv-cel临床试验取得积极成果；以星航运涨近9%，获瑞士航运集团收购要约
KYTX大涨超23%，Miv-cel临床试验取得积极成果；IMNM涨近16%，实验性药物晚期临床试验达主要终点；以星航运涨近9%，获瑞士航运集团收购要约>>
2025-12-16 19:53
Climb Bio Q3 EPS $(0.19) Misses $(0.14) Estimate
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.14) by 31.94 percent. This is a 46.15 percent decrease over losses of $(0.13) per share from the
2025-11-06 20:28
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
2025-10-21 05:08
Climb Bio Releases New Clinical Data on Budoprutug
Climb Bio ( ($CLYM) ) has shared an announcement. Climb Bio, Inc. announced on ...
2025-10-17 19:28
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
2025-10-17 09:58
